/conf_ser2021_txshift_covpn

Presentation "Causal evaluation of COVID-19 immune correlates of protection via stochastic intervention effects" for the annual meeting of the Society for Epidemiologic Research, June 2021

Primary LanguageCSS

SER 2021 Presentation

Oral Abstract Session Info

  • Title: Evaluation of causal vaccine efficacy under stochastic interventional shifts of an immunologic marker in COVID-19 vaccine efficacy trials
  • Keywords: causal inference, stochastic interventions, mediation analysis, interventional effects, two-phase sampling, immune correlate of protection, vaccine efficacy, COVID-19
  • Authors: Nima Hejazi, Peter Gilbert, David Benkeser
  • Session: Infectious Diseases: Oral abstract Session (Chair: Joanna Merckx)

Abstract

Initial efficacy assessments of vaccine candidates for COVID-19 have made for a promising start to curbing the pandemic. A critical next step is identifying immune correlates of protection, that could be used in the development of next-generation protective vaccine candidates. Deploying the classical tools of causal inference in service of such goals is obstructed by the historical focus of the field on static interventions, which cannot be applied to quantitative immunologic marker measurements without simplifying assumptions. Stochastic interventions, which define the target parameter as the mean counterfactual outcome under shifted versions of the observed immunologic marker distribution, hold promise for circumventing such difficulties. Complicating analytic efforts further, vaccine efficacy trials regularly employ two-phase sampling of immunologic markers, necessitating careful adjustment for formal statistical inference.

We present a novel framework for evaluating causal vaccine efficacy under stochastic interventional shifts of immunologic markers, with multiply robust, nonparametric-efficient estimators utilizing state-of-the-art machine learning in nuisance parameter estimation. Our effect definitions quantify how disease risk would change across counterfactual shifts of the observed immunogenicity of immunologic markers modulated by vaccination, similar to a dose-response analysis. Our framework readily incorporates corrections for two-phase sampling and right-censoring of disease endpoints, and defines vaccine efficacy by comparing counterfactual risks in vaccine and placebo arms. The approach, appearing in the correlates statistical analysis plan (https://doi.org/10.6084/m9.figshare.13198595) of the COVID-19 Prevention Network, is applied to mock data inspired by real-world vaccine efficacy trials to demonstrate how candidate correlates of protection may be evaluated by the impacts on disease risk of posited post-vaccination immunogenicity shifts.